Anti-Human ERBB2 Recombinant Antibody (Pertuzumab) (CAT#: TAB-053)

Recombinant monoclonal antibody to ERBB2. Pertuzumab (also called 2C4, trade name pertuzumab) is a monoclonal antibody. The first of its class in a line of agents called "HER dimerization inhibitors". By binding to HER2, it inhibits the dimerization of HER2 with other HER receptors, which is hypothesized to result in slowed tumor growth.


Specific Inquiry
  • Size:
  • Conjugation:
  • Endotoxin:
  • Purity:
  • Fc Engineering:
  • Published Data
  • Tested Data
  • Gene Expression
  • Datasheet
  • MSDS
  • COA

Figure 1 Pertuzumab enhanced degradation of ErbB3 in cells expressing high levels of ErbB2. (A) PAE.EGFR.ErbB3, MCF-7, PAE.

Figure 1 Pertuzumab enhanced degradation of ErbB3 in cells expressing high levels of ErbB2. (A) PAE.EGFR.ErbB3, MCF-7, PAE.

ErbB3 and SK-BR-3 cells were preincubated with or without 25 µg/ml pertuzumab (100 µg/ml for SK-BR-3 cells) for 1 h at 37°C. Cells were then incubated with or without CHX (25 µg/ml)) either without ligand, or with 10 nM HRG- β1 ECD, with or without pertuzumab, for 8 h at 37°C. The cells were lysed and subjected to western blotting using rabbit anti-ErbB3 and anti-tubulin (loading control) antibodies. This figure demonstrates one representative experiment out of a minimum of three. (B) Net luminescence values of bands corresponding to ErbB3 were quantified, normalized to the loading control. The average values of minimum three independent experiments ± standard deviation were plotted as percentage of control without CHX (indicated by the stippled line). Statistical analysis was performed and significant differences are indicated by asterisks (*). Single asterisk indicates P < 0.05, double asterisk indicates P < 0.01.

Sak, M. M., Szymanska, M., Bertelsen, V., Hasmann, M., Madshus, I. H., & Stang, E. (2013). Pertuzumab counteracts the inhibitory effect of ErbB2 on degradation of ErbB3. Carcinogenesis, 34(9), 2031-2038.

Figure 2 Pertuzumab enhances EGF-induced internalization of EGFR in cells expressing EGFR and ErbB2.

Figure 2 Pertuzumab enhances EGF-induced internalization of EGFR in cells expressing EGFR and ErbB2.

PAE cells stably expressing EGFR alone or EGFR and ErbB2 (A) and SKBr3 cells (B) were incubated with or without pertuzumab (25 μg/mL) for 1 h at 37°C and subsequently with 1 ng/mL 125 I-EGF at 37°C for the times indicated. The ratio of internalized to surface-localized 125 I-EGF was plotted as a function of time. Mean ± SE of three independent experiments with four parallels.

Hughes, J. B., Berger, C., Rødland, M. S., Hasmann, M., Stang, E., & Madshus, I. H. (2009). Pertuzumab increases epidermal growth factor receptor down-regulation by counteracting epidermal growth factor receptor-ErbB2 heterodimerization. Molecular cancer therapeutics, 1535-7163.

Figure 3 Pertuzumab doesnot affect EGF internalization inPAE cells expressing EGFR onlybut rescues EGF internalizationin PAE cell.

Figure 3 Pertuzumab doesnot affect EGF internalization inPAE cells expressing EGFR onlybut rescues EGF internalizationin PAE cell.

A,PAE.EGFR andPAE.EGFR.ErbB2 cells were incu-batedwithAlexa555-EGF(60 ng/mL) for 15 min at 37°C.The cells were fixed and immu-nostained using rabbit anti-EEA1antibody followed by Alexa 647-conjugated donkey anti-rabbitantibody.B,PAE.EGFR and PAE.EGFR.ErbB2cellswereincubatedwith pertuzumab (25μg/mL) for1 h at 37°C followed by Alexa555-EGF (60 ng/mL) for 15 minat 37°C and subsequently fixedand stained as described inA.Endocytosed EGF is observed tocolocalize with EEA1 in early en-dosomes (pinkdots).

Hughes, J. B., Berger, C., Rødland, M. S., Hasmann, M., Stang, E., & Madshus, I. H. (2009). Pertuzumab increases epidermal growth factor receptor down-regulation by counteracting epidermal growth factor receptor-ErbB2 heterodimerization. Molecular cancer therapeutics, 1535-7163.

Figure 4 Impact of therapeutics on EGF-induced fast signaling.

Figure 4 Impact of therapeutics on EGF-induced fast signaling.

Data show EGF-induced ERK1/2 (a and c) and AKT (b and d) phosphorylation after preincubation of SKBR3 cells with trastuzumab, pertuzumab or erlotinib (a and b), as well as with all possible combinations (c and d). Phosphorylation dynamics were analyzed by RPPA. EGF (5 nM) induced phosphorylation of AKT and ERK1/2 in serum-starved SKBR3 cells. Pertuzumab and trastuzumab downregulated AKT signaling, whereas erlotinib, applied alone and in all combinations with therapeutic antibodies, inhibited the activation of both the pathways. Corresponding data set for HCC1954 cells is shown as Supplementary Figure S3 and Supplementary Table S1.

Henjes, F., Bender, C., Von Der Heyde, S., Braun, L., Mannsperger, H. A., Schmidt, C., ... & Korf, U. (2012). Strong EGFR signaling in cell line models of ERBB2-amplified breast cancer attenuates response towards ERBB2-targeting drugs. Oncogenesis, 1(7), e16.


Specifications

  • Immunogen
  • The details of the immunogen for this antibody are not available.
  • Host Species
  • Mouse
  • Derivation
  • Humanized (from mouse)
  • Type
  • IgG1 - kappa
  • Specificity
  • Tested positive against native human antigen.
  • Species Reactivity
  • Human
  • Applications
  • FuncS, IF, Neut, ELISA, FC, IP, WB
  • Trade name
  • pertuzumab, Omnitarg
  • CAS
  • 380610-27-5
  • Generic Name
  • Pertuzumab
  • ATC Code
  • L01XC13
  • UNII
  • K16AIQ8CTM
  • ChEMBL
  • CHEMBL2007641
  • Related Disease
  • Prostate cancers

Product Property

  • Purity
  • >95.0% as determined by Analysis by RP-HPLC & analysis by SDS-PAGE.
  • Storage
  • Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles.

Applications

  • Application Notes
  • The ERBB2 antibody has been reported in applications of WB, Internalization, IF, Inhib.
    Inhibition: In short-term experiments, trastuzumab (10 ng/μl), pertuzumab (10 ng/μl) and erlotinib (1 μM) were added to cells in starvation medium either alone or in combinations 1 h prior to growth-factor stimulation.

Target

  • Alternative Names
  • Pertuzumab;pertuzumab, Omnitarg;380610-27-5;rhuMAb 2C4;RG1273;pertuzumab;2C4;pertuzumab;Omnitarg;ERBB2;v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian);NGL, v erb b2 avian erythroblastic leukemia viral

Related Resources

  • Related Diseases
  • Related Signaling Pathways

Product Notes

This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:

• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production

See more details about Hi-Affi™ recombinant antibody benefits.

Downloads

Download resources about recombinant antibody development and antibody engineering to boost your research.

See other products for "Pertuzumab"

Afuco™ Anti-ERBB2 ADCC Recombinant Antibody (Pertuzumab), ADCC Enhanced
This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant monoclonal antibody to ERBB2. Pertuzumab (also called 2C4, trade name pertuzumab) is a monoclonal antibody. The first of its class in a line of agents called "HER dimerization inhibitors". By binding to HER2, it inhibits the dimerization of HER2 with other HER receptors, which is hypothesized to result in slowed tumor growth.

See other products for "ERBB2"

Intrabody

CAT Product Name Application Type
IAB-B008(A) Recombinant Anti-human ERBB2 Intrabody [(D-Arg)9] IF, FC, FuncS scFv-(D-Arg)9
IAB-B008(G) Recombinant Anti-human ERBB2 Intrabody [+36 GFP] WB, ICC, FuncS scFv-(+36GFP)
IAB-B008(T) Recombinant Anti-human ERBB2 Intrabody [Tat] ICC, Neut, FuncS scFv-Tat

Humanized Antibody

CAT Product Name Application Type
TAB-005 Anti-Human ErbB2 Recombinant Antibody (Trastuzumab) FC, IP, ELISA, Neut, FuncS, IF, IHC IgG1 - kappa
TAB-H70 Anti-Human ERBB2 Recombinant Antibody (Trastuzumab Emtansine) ELISA, IP, FC, FuncS, Neut, IF, ICC IgG1 - kappa
TAB-050CT-F(E) Anti-Human HER2/neu Recombinant Antibody Fab Fragment (HuA21) ELISA, WB Humanized antibody
TAB-053CT-F(E) Human Anti-ERBB2 Recombinant Antibody; Fab Fragment (TAB-053CT-F(E)) ELISA, Inhib, FC Humanized Fab
TAB-054CT-F(E) Humanized Anti-Human HER2/neu Recombinant Antibody Fab Fragment ELISA, Inhibition, FC Humanized antibody

Chimeric Antibody

CAT Product Name Application Type
TAB-761 Anti-ERBB2 Recombinant Antibody (Margetuximab) IF, IP, Neut, FuncS, ELISA, FC, WB IgG1 - kappa
TAB-049CT Anti-Human HER2/neu Recombinant Antibody (ChA21) IHC, Inhib, WB, Activ, FC Chimeric antibody (mouse/human)
TAB-049CT-S(P) Anti-Human HER2/neu Recombinant Antibody scFv Fragment (ChA21) WB Chimeric antibody (mouse/human)
TAB-049CT-F(E) Anti-Human HER2/neu Recombinant Antibody Fab Fragment (ChA21) WB Chimeric antibody (mouse/human)

Immunotoxin

CAT Product Name Application Type
AGTO-G022E Anti-ERBB2 immunotoxin 4D5 (scFv)-PE Cytotoxicity assay, Function study
AGTO-G022D Anti-ERBB2 immunotoxin 4D5 (scFv)-DT Cytotoxicity assay, Function study
AGTO-G022G Anti-ERBB2 immunotoxin 4D5 (scFv)-Gel Cytotoxicity assay, Function study
AGTO-G022R Anti-ERBB2 immunotoxin 4D5 (scFv)-RTA Cytotoxicity assay, Function study
AGTO-G022S Anti-ERBB2 immunotoxin 4D5 (scFv)-Sap Cytotoxicity assay, Function study

Fab Glycosylation

Deglycosylated Antibody (Non-glycosylated IgGs)

CAT Product Name Application Type
Gly-177LC Recombinant Anti-Human ERBB2 Antibody (Non-glycosylated) ELISA Humanized antibody

Chicken IgY Antibody

CAT Product Name Application Type
BRD-0195MZ Chicken Anti-ERBB2 Polyclonal IgY WB Chicken antibody
BRD-0695MZ Chicken Anti-ERBB2 Polyclonal IgY WB Chicken antibody
BRD-0779MZ Chicken Anti-ErbB2 Polyclonal IgY ICC, IF, IHC, IP Chicken antibody

Blocking Antibody

CAT Product Name Application Type
NEUT-737CQ Mouse Anti-ERBB2 Recombinant Antibody (clone 7.16.4) Block, IP, IF, FC Mouse IgG2a

ADCC Enhanced Antibody

CAT Product Name Application Type
AFC-TAB-468CQ Afuco™ Anti-ERBB2 ADCC Recombinant Antibody (Timigutuzumab), ADCC Enhanced ELISA, IHC, FC, IP, IF, FuncS ADCC enhanced antibody
AFC-TAB-053 Afuco™ Anti-ERBB2 ADCC Recombinant Antibody (Pertuzumab), ADCC Enhanced FuncS, IF, Neut, ELISA, FC, IP ADCC enhanced antibody
AFC-TAB-761 Afuco™ Anti-ERBB2 ADCC Recombinant Antibody (Margetuximab), ADCC Enhanced IF, IP, Neut, FuncS, ELISA, FC ADCC enhanced antibody
AFC-TAB-005 Afuco™ Anti-ERBB2 ADCC Recombinant Antibody (Trastuzumab), ADCC Enhanced FC, IP, ELISA, Neut, FuncS, IF ADCC enhanced antibody

Customer Reviews and Q&As

Submit a review or a question
There are currently no Customer reviews or questions for TAB-053. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.

For Research Use Only. Not For Clinical Use.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Send Inquiry

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

© 2024 Creative Biolabs.
  • 0
  • 0
Cart

    Go to compare